Our website uses cookies

Essential and functional cookies are necessary for the website to function properly and cannot be refused. Other cookies are used for statistical purposes (analysis cookies) and will only be placed if you agree to their placement. See our cookie policy to find out more.

Accept cookies Accept essential cookies only

Disclaimer

You are leaving serb.eu global website.

This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. Serb declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, Serb is not responsible for any information or opinion contained in any third-party website.

OK Cancel

We focus on
KEEPING YOU UPDATED

Mar 30 2021

SERB acquires Veriton Pharma

SERB expands presence in UK specialty pharmaceuticals and strengthens its neurology and rare disease franchise with the acquisition of Veriton Pharma.

Veriton Pharma, a private pharmaceutical company specialising in the development of licensed and unlicensed medicines for patients with neurological conditions and rare metabolic diseases.

 

READ THE VERITON PRESS RELEASE
VISIT THE Veriton Pharma WEBSITE